CN111465399A - 抗cd40抗体药物结合物 - Google Patents

抗cd40抗体药物结合物 Download PDF

Info

Publication number
CN111465399A
CN111465399A CN201880077793.3A CN201880077793A CN111465399A CN 111465399 A CN111465399 A CN 111465399A CN 201880077793 A CN201880077793 A CN 201880077793A CN 111465399 A CN111465399 A CN 111465399A
Authority
CN
China
Prior art keywords
antibody drug
drug conjugate
antibody
amino
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880077793.3A
Other languages
English (en)
Chinese (zh)
Inventor
A.D.霍布森
J.Z.区
M.J.麦克菲尔森
W.维格尔
S.H.布赖恩特
A.小埃尔南德斯
C.L.伊勒
C.C.马文
O.A.佩尔恩
L.C.桑托拉
王璐
王路
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CN111465399A publication Critical patent/CN111465399A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880077793.3A 2017-12-01 2018-11-29 抗cd40抗体药物结合物 Pending CN111465399A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762593807P 2017-12-01 2017-12-01
US62/593807 2017-12-01
US201762595045P 2017-12-05 2017-12-05
US62/595045 2017-12-05
PCT/IB2018/059480 WO2019106608A1 (en) 2017-12-01 2018-11-29 Anti-cd40 antibody drug conjugates

Publications (1)

Publication Number Publication Date
CN111465399A true CN111465399A (zh) 2020-07-28

Family

ID=66663861

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880077793.3A Pending CN111465399A (zh) 2017-12-01 2018-11-29 抗cd40抗体药物结合物

Country Status (19)

Country Link
US (1) US20220265842A1 (https=)
EP (1) EP3716982A4 (https=)
JP (1) JP2021504430A (https=)
KR (1) KR20200095493A (https=)
CN (1) CN111465399A (https=)
AU (1) AU2018374633A1 (https=)
BR (1) BR112020010691A2 (https=)
CA (1) CA3081559A1 (https=)
CL (1) CL2020001442A1 (https=)
CR (1) CR20200285A (https=)
DO (1) DOP2020000119A (https=)
EC (1) ECSP20034868A (https=)
IL (1) IL274650A (https=)
MX (1) MX2020005465A (https=)
PE (1) PE20201464A1 (https=)
PH (1) PH12020550551A1 (https=)
RU (1) RU2020117156A (https=)
SG (1) SG11202004865SA (https=)
WO (1) WO2019106608A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022166779A1 (zh) * 2021-02-04 2022-08-11 上海森辉医药有限公司 糖皮质激素受体激动剂的药物偶联物及其在医药上的应用
WO2022268176A1 (zh) * 2021-06-24 2022-12-29 江苏先声药业有限公司 甾体类化合物、其药物组合物及其应用
WO2023025248A1 (zh) * 2021-08-26 2023-03-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
WO2023040793A1 (zh) * 2021-09-14 2023-03-23 映恩生物制药（苏州）有限公司 一种抗炎症的化合物及其用途
CN116888137A (zh) * 2021-03-23 2023-10-13 伊莱利利公司 羧基取代的糖皮质激素受体激动剂
WO2024140903A1 (zh) * 2022-12-28 2024-07-04 苏州盛迪亚生物医药有限公司 一种cd40结合分子的组合物及医药用途
WO2024140917A1 (zh) * 2022-12-28 2024-07-04 上海盛迪医药有限公司 抗cd40抗体药物偶联物、其制备方法及其医药用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113271964A (zh) 2019-01-11 2021-08-17 诺华股份有限公司 化脓性汗腺炎治疗中使用的抗cd40抗体
AU2022205664A1 (en) * 2021-01-07 2023-08-17 Immunext, Inc. NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF
AR125084A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas del receptor de glucocorticoides novedosos
CN117043172A (zh) * 2021-03-23 2023-11-10 伊莱利利公司 糖皮质激素受体激动剂
TWI899455B (zh) 2021-03-23 2025-10-01 美商美國禮來大藥廠 糖皮質素受體激動劑
KR102835682B1 (ko) * 2022-06-16 2025-07-22 애브비 바이오테라퓨틱스 인크. 항-cd19 항체-약물 접합체
CN120239705A (zh) 2022-07-21 2025-07-01 萤火虫生物股份有限公司 糖皮质激素受体激动剂和其缀合物
JP2025532110A (ja) * 2022-09-22 2025-09-29 イーライ リリー アンド カンパニー グルココルチコイド受容体アゴニスト
WO2026035986A1 (en) 2024-08-07 2026-02-12 Bighat Biosciences, Inc. Humanized anti-cdh17 antibodies and use of the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140336160A1 (en) * 2007-11-30 2014-11-13 Pfizer Inc. Novel glucocorticold receptor agonists
US20160347850A1 (en) * 2015-05-29 2016-12-01 Abbvie Inc. Anti-cd40 antibodies and uses thereof
CN109476699A (zh) * 2016-06-02 2019-03-15 艾伯维公司 糖皮质激素受体激动剂及其免疫偶联物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085879A2 (en) * 2007-12-21 2009-07-09 Schering Corporation C20-c21 substituted glucocorticoid receptor agonists
ES2709654T3 (es) * 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US10550190B2 (en) * 2014-04-04 2020-02-04 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140336160A1 (en) * 2007-11-30 2014-11-13 Pfizer Inc. Novel glucocorticold receptor agonists
US20160347850A1 (en) * 2015-05-29 2016-12-01 Abbvie Inc. Anti-cd40 antibodies and uses thereof
CN109476699A (zh) * 2016-06-02 2019-03-15 艾伯维公司 糖皮质激素受体激动剂及其免疫偶联物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOBSON, A.，等: "Discovery of abbv-3373, an anti-TNF glucocorticoid receptor modulator immunology antibody drug conjugate", JOURNAL OF MEDICINAL CHEMISTRY, vol. 65, 17 November 2022 (2022-11-17), pages 15893 - 15934, XP093076535, DOI: 10.1021/acs.jmedchem.2c01579 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022166779A1 (zh) * 2021-02-04 2022-08-11 上海森辉医药有限公司 糖皮质激素受体激动剂的药物偶联物及其在医药上的应用
CN116761820A (zh) * 2021-02-04 2023-09-15 上海森辉医药有限公司 糖皮质激素受体激动剂的药物偶联物及其在医药上的应用
CN116761820B (zh) * 2021-02-04 2026-01-13 上海森辉医药有限公司 糖皮质激素受体激动剂的药物偶联物及其在医药上的应用
CN116888137A (zh) * 2021-03-23 2023-10-13 伊莱利利公司 羧基取代的糖皮质激素受体激动剂
WO2022268176A1 (zh) * 2021-06-24 2022-12-29 江苏先声药业有限公司 甾体类化合物、其药物组合物及其应用
WO2023025248A1 (zh) * 2021-08-26 2023-03-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
CN117500816A (zh) * 2021-08-26 2024-02-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
CN117500816B (zh) * 2021-08-26 2025-03-28 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
WO2023040793A1 (zh) * 2021-09-14 2023-03-23 映恩生物制药（苏州）有限公司 一种抗炎症的化合物及其用途
WO2024140903A1 (zh) * 2022-12-28 2024-07-04 苏州盛迪亚生物医药有限公司 一种cd40结合分子的组合物及医药用途
WO2024140917A1 (zh) * 2022-12-28 2024-07-04 上海盛迪医药有限公司 抗cd40抗体药物偶联物、其制备方法及其医药用途

Also Published As

Publication number Publication date
SG11202004865SA (en) 2020-06-29
JP2021504430A (ja) 2021-02-15
ECSP20034868A (es) 2020-08-31
WO2019106608A1 (en) 2019-06-06
DOP2020000119A (es) 2020-08-31
IL274650A (en) 2020-06-30
US20220265842A1 (en) 2022-08-25
MX2020005465A (es) 2020-09-07
PE20201464A1 (es) 2020-12-17
KR20200095493A (ko) 2020-08-10
PH12020550551A1 (en) 2021-03-22
CA3081559A1 (en) 2019-06-06
AU2018374633A1 (en) 2020-05-21
CR20200285A (es) 2020-09-04
RU2020117156A (ru) 2022-01-04
EP3716982A4 (en) 2021-08-11
CL2020001442A1 (es) 2020-09-11
BR112020010691A2 (pt) 2020-11-10
EP3716982A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
CN111465399A (zh) 抗cd40抗体药物结合物
JP6813712B2 (ja) グルココルチコイド受容体作動薬及びそのイムノコンジュゲート
CN112004557B (zh) 类固醇类化合物及其抗体偶联物
KR102435599B1 (ko) 글루코코르티코이드 수용체 작용제 및 이의 면역접합체
KR102713173B1 (ko) 비스-옥타하이드로페난트렌 카복스아미드 및 이의 단백질 접합체
CN112533951A (zh) 抗msr1抗体及其使用方法
CN115651056A (zh) 类固醇类化合物及其蛋白质-偶联物
TW202404648A (zh) 抗體－吡咯并苯二氮呯衍生物複合體
CN119264215A (zh) 无痕连接体及其蛋白质偶联物
HK40032698A (en) Anti-cd40 antibody drug conjugates
WO2026026939A1 (zh) 抗cd74抗体、抗体-药物缀合物及其制备方法和用途
WO2025252194A1 (zh) 抗体-激素药物偶联物及其用途
CN120659785A (zh) Tlr7激动剂及其抗体-药物缀合物
HK40031135B (en) Glucocorticoid receptor agonist and immunoconjugates thereof
HK40031135A (en) Glucocorticoid receptor agonist and immunoconjugates thereof
EA046890B1 (ru) Гидрофильные линкеры для конъюгатов антитело-лекарственное средство

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40032698

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200728